We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




World’s First Rapid Diagnostic Test Detects Stroke within Minutes at POC

By LabMedica International staff writers
Posted on 19 Jul 2024
Print article
Image: The LVOne point-of-care rapid test can recognize LVO stroke cases within 15 minutes (Photo courtesy of UpFront Diagnostics)
Image: The LVOne point-of-care rapid test can recognize LVO stroke cases within 15 minutes (Photo courtesy of UpFront Diagnostics)

Each year, more than 20 million people worldwide suffer from strokes. Large vessel occlusions (LVO) constitute 30% of these cases but are behind 95% of the resulting disabilities and fatalities. The likelihood of recovery improves significantly if a procedure known as 'thrombectomy' is performed immediately after the onset of symptoms. However, speeding up this treatment is complicated because it's difficult to identify LVO strokes outside hospital settings; symptoms can mimic other medical issues. Strokes can also result from blockages in smaller vessels or vessel ruptures, neither of which are suitable for thrombectomy. Ideally, LVO strokes need to be diagnosed quickly and before the patient arrives at the hospital to speed up the initiation of thrombectomy. Currently, there is no sufficiently accurate diagnostic tool for this purpose. Now, a groundbreaking diagnostic test can identify an LVO stroke within 15 minutes, expediting patient transfer to specialized care and saving more than 1 hour 30 minutes over the current clinical pathway.

The innovative LVOne test from UpFront Diagnostics (Cambridge, UK) employs a combination of blood-based biomarkers and clinical scoring to accurately detect patients undergoing an LVO stroke. The Testing for Identification Markers of strokE (TIME) clinical study has confirmed the efficacy of UpFront’s specific blood biomarkers GFAP and D-dimer, achieving 90% accuracy in identifying LVO strokes. This prospective, observational diagnostic accuracy study analyzed data from 323 patients suspected of stroke. It demonstrated that integrating GFAP and D-dimer biomarker levels with FAST-ED scores within six hours of symptom onset allows the LVOne test to achieve 93% specificity and 81% sensitivity in detecting LVO strokes. The test also successfully excluded all patients with brain hemorrhages, suggesting potential future applications in identifying intracerebral hemorrhages in the field.

Published in the open-access journal Stroke: Vascular and Interventional Neurology, these outstanding results build on previous UK clinical trials by UpFront Diagnostics, paving the way for pre-hospital identification of LVO stroke patients. Implementing this biomarker strategy in the field could significantly reduce the time to thrombectomy, lower disability risks, and the associated medical and social costs of strokes. Moreover, GFAP and D-dimer have emerged as leading biomarkers for LVO stroke detection in pre-hospital settings. The LVOne test holds great promise for future deployment in low- and middle-income countries where advanced imaging technologies may be unavailable. It might also find use in evaluating traumatic brain injuries. Future studies will test the LVOne device’s efficacy in ambulances and an interventional trial will explore its potential to streamline stroke patient triage by bypassing conventional imaging and proceeding directly to therapeutic interventions.

Related Links:
UpFront Diagnostics

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Amoebiasis Test
ELI.H.A Amoeba
New
Bead-Based Multiplex Assay
Human Luminex Discovery Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.